Compare ENHA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENHA | PRME |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.1M | 526.0M |
| IPO Year | 2025 | 2022 |
| Metric | ENHA | PRME |
|---|---|---|
| Price | $1.09 | $3.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $4.00 | ★ $7.11 |
| AVG Volume (30 Days) | 704.2K | ★ 4.5M |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | N/A | $90.65 |
| Revenue Next Year | $168.06 | $19.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $1.06 | $2.67 |
| 52 Week High | $4.60 | $5.10 |
| Indicator | ENHA | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 52.12 |
| Support Level | $1.06 | $2.89 |
| Resistance Level | $1.62 | $3.64 |
| Average True Range (ATR) | 0.15 | 0.36 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 12.00 | 50.68 |
Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.